Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

Simple item page
dc.contributor.authorRichter Igorcs
dc.contributor.authorPoprach Alexandrcs
dc.contributor.authorZemánková Anežkacs
dc.contributor.authorBuchler Tomášcs
dc.contributor.authorBartoš Jiřícs
dc.contributor.authorŠámal Vladimírcs
dc.contributor.authorRozsypalová Anetacs
dc.contributor.authorDvořák Josefcs
dc.contributor.authorBrom Ondřejcs
dc.contributor.authorMelichar Bohuslavcs
dc.contributor.authorStudentová Hanacs
dc.date.accessioned2022-01-29T18:14:15Z
dc.date.available09-41-2021en
dc.date.available2022-01-29T18:14:15Z
dc.date.issued2020cs
dc.identifier.doi10.5507/bp.2020.055
dc.identifier.issn1213-8118cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/161634
dc.language.isoengcs
dc.publisherPalacky University Olomouccs
dc.relation.ispartofBiomedical Papersen
dc.relation.urihttp://biomed.papers.upol.cz/doi/10.5507/bp.2020.055.pdfcs
dc.subjectcabozantinibcs
dc.subjectmetastasescs
dc.subjectrenal cell carcinomacs
dc.subjecttoxicitycs
dc.titlePatients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centersen
dc.titlePatients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centerscs
local.identifier.publikace8331
Files
Collections